Zaloguj Zarejestruj się zadarmo

Genocea Biosciences Inc organizacji Cena/Sprzedaż

Jaka jest wartość Cena/Sprzedaż organizacji Genocea Biosciences Inc?

Wartość Cena/Sprzedaż organizacji Genocea Biosciences Inc to 0.07

Jaka jest definicja Cena/Sprzedaż?



Wskaźnik ceny do zysku (Price to sales ratio) to wskaźnik reprezentuje koszt firmy w porównaniu do kwoty jej sprzedaży.

The price to sales ratio, Price/Sales ratio, P/S ratio, or PSR, is a valuation metric for stocks. It is calculated by dividing the company's market cap by the revenue in the most recent year. It can also be calculated by dividing the per-share stock price by per-share revenue. The price to sales ratio is for trailing twelve months so the reported sales are for the four previous quarters. Longer time periods can be examined at times.

A smaller price to sales ratio is usually thought to be a better investment since the investor is paying less for each unit of sales. However, sales do not reveal the whole picture, as the company may be unprofitable with a low P/S ratio. Because of the limitations, this ratio is usually used only for unprofitable companies, since they don't have a price to earnings ratio (P/E ratio). The metric can be used to determine the value of a stock relative to its past performance. It may also be used to determine relative valuation of a sector or the market as a whole.

Price to sales ratios vary greatly between sectors, so they are most useful in comparing similar stocks within a sector or sub-sector. Comparing P/S ratios carries the implicit assumption that all firms in the comparison have an identical capital structure.

Cena/Sprzedaż firm w Health Care sektor na NASDAQ w porównaniu do Genocea Biosciences Inc

Czym się zajmuję organizacja Genocea Biosciences Inc?

Genocea's mission is to conquer cancer by developing personalized cancer immunotherapies in multiple tumor types. Our unique ATLAS™ platform comprehensively profiles each patient's T cell responses to potential targets, or antigens, on the tumor. ATLAS enables us to optimize the neoantigens for inclusion in our immunotherapies and exclude inhibitory antigens, Inhibigens™, that can exert an immunosuppressive effect. We are advancing two ATLAS-enabled programs: GEN-009, our neoantigen vaccine and GEN-011, our neoantigen-specific cell therapy using T cells derived from peripheral blood.

Firmy z cena/sprzedaż podobne do Genocea Biosciences Inc